← All articles

GHK-Cu vs AHK-Cu: What Hair Research Actually Studied

Bookmark this page

Save this article in your browser so you can find it again:

  • Computer: Press Ctrl+D (Windows) or ⌘+D (Mac).
  • iPhone or iPad: In Safari, tap Share, then Add Bookmark.
  • Android: In Chrome, open the menu and tap the star.

Other browsers may use a different menu.

GHK-Cu and AHK-Cu are different copper complexes. Their hair evidence spans isolated tissue, animal experiments and small human reports. The studies do not establish which is better for scalp hair loss.

The evidence is more informative when each result stays attached to the molecule, formulation, body site and study design. “Human hair” in a title may describe the source of tissue rather than a trial in people.

Publisher disclosure: Bio Research LLC operates Bio Peptides Labs and sells GHK-Cu-labeled laboratory materials. This is commercially interested, AI-assisted editorial content, not an independent scientific review. Selected primary sources were checked November 11, 2026. Full reports were available for several studies; the AHK-Cu and microemulsion summaries relied on original abstracts. No individual participant data were reviewed.

Hair evidence map distinguishes AHK-Cu experiments in isolated human follicles, a small GHK-Cu eyebrow-serum report and separate scalp-formulation evidence. These settings do not establish a clinical ranking.
Isolated follicles, eyebrows and scalp studies answer different questions. Their materials and endpoints do not establish that GHK-Cu or AHK-Cu is better for scalp hair loss.

How do GHK-Cu and AHK-Cu differ?

GHK contains glycine, histidine and lysine; AHK substitutes alanine for glycine. Their copper complexes are different materials. A shared “copper peptide” label cannot identify which one an experiment tested.

Another distinction is GHK without copper. A study of a GHK-containing conjugate or multi-ingredient formulation should not silently become evidence for GHK-Cu alone. The GHK-Cu laboratory overview provides the broader molecular and experimental context.

The comparison below concerns evidence, not a recommendation to select a treatment or research vial for personal use.

Which molecule did each study test?

Research evidence map

Study

Material and model

Comparison and observation

Main limitation

Pyo, 2007

AHK-Cu; isolated human follicles and cultured dermal papilla cells

Laboratory controls; follicle elongation and cell proliferation

No treated patient group; donor count not available in the inspected abstract

Lee, 2016

GHK linked with 5-aminolevulinic acid; reported 45 men

Two active groups and placebo; six months

Formulation is not GHK-Cu; participant counts differ between sections

Liu, 2023

GHK-Cu in a microemulsion; skin models and mice

Delivery and hair-related measurements

Engineered carrier and animal endpoints do not establish human regrowth

Bo, 2026

GHK-Cu serum; 18 adults, split-face

Vehicle on the other eyebrow; 12 weeks

Small proceedings report; eyebrow findings do not establish scalp effects

These are not four independent trials of the same intervention. They address different questions and cannot be pooled into a percentage of people who benefit from “copper peptides.”

What does the AHK-Cu follicle experiment show?

Pyo and colleagues reported elongation of follicles maintained outside the body and increased proliferation of cultured dermal papilla cells. A reduction in apoptotic cells did not reach statistical significance, although some related molecular markers changed. Reporting that distinction is more accurate than saying the study proved prevention of cell death.

This experiment supplies a biological research signal. It does not report scalp-hair counts after treatment in patients, durable improvement, or a comparison with GHK-Cu in people. The tissue's human origin does not resolve those gaps.

An endpoint also matters independently of the molecule. Longer growth of an isolated follicle during culture is not the same measurement as improved density across a person's scalp. Moving from one claim to the other requires additional evidence, not a change in terminology.

What do the human reports add?

The 2026 eyebrow report describes randomized side allocation and blinded assessment. At week 12, the active and vehicle sides averaged 30.50 and 28.67 hairs in the 1-cm² measured region, respectively; the paired difference was 1.83 hairs, with p = 0.049. This is a small observed comparison, not a scalp regrowth rate or a measure of permanence. Eighteen participants do not become 36 independent participants because both eyebrows were evaluated.

The 2016 study tested a 5-aminolevulinic-acid–GHK conjugate. One active group had a significant hair-count comparison with placebo, while hair length and thickness did not differ significantly between groups. The report describes 45 completers but lists 15/14/14 in one methods passage and 15 per group elsewhere. That inconsistency should remain visible rather than being silently repaired. Neither the compound identity nor the reporting supports treating it as a GHK-Cu-alone trial.

A separate 2024 scalp study examined a scrub plus a serum containing copper tripeptide and other ingredients. It enrolled 32 adults with dandruff; 29 completed 15 days. Although it reported hair measurements, the open-label, uncontrolled combination design cannot isolate the peptide or establish sustained regrowth. The paper disclosed research-company and manufacturer relationships. Original scalp-regimen study.

Why do formulation and study setting prevent a ranking?

The microemulsion paper, published online in 2023 with a 2024 collection date, investigated an engineered delivery system and reported hair-related effects in mice. Its observations belong to that formulation and model. They do not establish that an ordinary serum has the same delivery, or that GHK-Cu is safer or more effective than an established medicine in people.

To compare AHK-Cu with GHK-Cu meaningfully, a study would need to define both materials, use comparable formulations and evaluate the same population and endpoints. It should account for baseline differences, assess harms, report missing follow-up and distinguish cosmetic appearance from sustained clinical change. The selected studies do not provide that comparison.

Likewise, mixing two ingredients because each has separate laboratory findings is not evidence of an effective combination. A formulation-specific study must examine the combination itself and use controls that can answer the question being asked.

For skin-formulation questions, see the separate topical GHK-Cu guide. For interpretation of tolerability and route differences, read the GHK-Cu safety evidence guide. Neither article provides a dosing, mixing or administration protocol.

Review method and source access

This was a focused search of primary publication records, publisher reports and ClinicalTrials.gov, not a systematic review or proof that no other studies exist. The eyebrow proceedings PDF, GHK conjugate and scalp-regimen reports were read in full. AHK-Cu and microemulsion summaries used original abstracts, with indexed figure captions also inspected for the latter. A newer registry describing multiple topical peptides had no posted results and was not counted as efficacy evidence. Catalog materials are for lawful laboratory research only, not human or veterinary use.

Are GHK-Cu and AHK-Cu the same copper peptide?

No. They are differently named copper-peptide materials, and a result for a particular formulation or study model should stay attached to that material. The studies reviewed here do not establish which is better for hair. The GHK-Cu laboratory guide discusses material identification separately.

References

On November 19, 2026, we rechecked the AHK-Cu and 2016 GHK-conjugate abstracts, the eyebrow proceedings abstract and the named registry record. The registry had no posted results when checked. The earlier full-report and figure-caption checks retain their original scope; this update was not a systematic search or an independent analysis of participant data.